HCAT vs. SABR, FSLY, BASE, YALA, MOMO, GDYN, DAVA, HUYA, EVER, and RCAT
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Sabre (SABR), Fastly (FSLY), Couchbase (BASE), Yalla Group (YALA), Hello Group (MOMO), Grid Dynamics (GDYN), Endava (DAVA), HUYA (HUYA), EverQuote (EVER), and Red Cat (RCAT). These companies are all part of the "computer software" industry.
Health Catalyst vs. Its Competitors
Health Catalyst (NASDAQ:HCAT) and Sabre (NASDAQ:SABR) are both small-cap computer software companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Health Catalyst presently has a consensus price target of $8.00, suggesting a potential upside of 112.20%. Sabre has a consensus price target of $4.28, suggesting a potential upside of 43.46%. Given Health Catalyst's stronger consensus rating and higher possible upside, analysts plainly believe Health Catalyst is more favorable than Sabre.
Health Catalyst has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Sabre has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
In the previous week, Sabre had 6 more articles in the media than Health Catalyst. MarketBeat recorded 8 mentions for Sabre and 2 mentions for Health Catalyst. Sabre's average media sentiment score of 0.23 beat Health Catalyst's score of 0.01 indicating that Sabre is being referred to more favorably in the news media.
Health Catalyst has higher earnings, but lower revenue than Sabre. Sabre is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 89.4% of Sabre shares are owned by institutional investors. 2.6% of Health Catalyst shares are owned by company insiders. Comparatively, 2.3% of Sabre shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Sabre has a net margin of -5.69% compared to Health Catalyst's net margin of -23.34%. Sabre's return on equity of 0.00% beat Health Catalyst's return on equity.
Summary
Health Catalyst and Sabre tied by winning 8 of the 16 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Health Catalyst Competitors List
Related Companies and Tools
This page (NASDAQ:HCAT) was last updated on 6/26/2025 by MarketBeat.com Staff